GRADE 3B FOLLICULAR LYMPHOMA
Clinical trials for GRADE 3B FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new GRADE 3B FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for GRADE 3B FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Two-Drug combo shows promise for Tough-to-Treat lymphomas
Disease control OngoingThis early-stage study tested a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system attack cancer) and vorinostat (a drug that blocks enzymes cancer cells need to grow)—in 52 people with certain types of lymphoma that had returned or stopped resp…
Matched conditions: GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 16, 2026 13:01 UTC
-
New combo attack on tough lymphoma shows promise
Disease control OngoingThis study tests whether combining the drug acalabrutinib with a cell therapy called liso-cel can shrink or eliminate aggressive B-cell lymphomas that have returned or not responded to prior treatments. About 28 adults with these hard-to-treat cancers will receive the combination…
Matched conditions: GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: Patrick C. Johnson, MD • Aim: Disease control
Last updated Jun 16, 2026 12:53 UTC
-
New combo therapy aims to extend remission in elderly lymphoma patients
Disease control OngoingThis study is for people aged 75 or older who have been newly diagnosed with certain aggressive types of B-cell lymphoma. It tests whether adding an oral medication (CC-486, or oral azacitidine) to the standard reduced-dose chemotherapy regimen (R-miniCHOP) can help keep the canc…
Matched conditions: GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC